TUBGCP6 and hepatocellular carcinoma: CLDN18 was overexpressed in 28.49% of the TP53 mutant (P = 9.46E-06) and 1.12% of TUBGCP6 mutant HCC tissues compared to the wild-type tumors (Fig. 5A, B).